Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Łazar-Poniatowska, Małgorzata; Bandura, Artur Szymon; Dziadziuszko, Rafał; Jassem, Jacek

doi:10.21037/tlcr-20-704

Cited by 9 publications

(6 citation statements)

References 72 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSCLC survival improves with diagnostic, surgical, radiotherapy procedures, and medical treatments. Administering platinum-based chemotherapy sequentially or concurrently to thoracic irradiation resulted in a improvement of local control, metastasis-free and overall survival 8 . In the studies of Yılmaz U et al, complete and partial responses were obtained in 15 (18.2%) and 31 (37.8%) Stage IIIA and IIIB patients who underwent definitive CRT 9 .…”

Section: Resultsmentioning

confidence: 98%

Effect of Covid-19 pandemic on patients undergoing definitive chemoradiotherapy

Karaman¹,

Ulaş²

2022

CMJ

View full text Add to dashboard Cite

Lung cancer is frequently seen in patients who smoke, who are elderly, and who have more comorbid diseases. The risk of being affected by the Covid-19 pandemic is high. Here, we aimed to determine the effectiveness of the definitive chemoradiotherapy (CRT) in patients with non metastatic non-small cell lung cancers (NSCLC) during the pandemic period. Patients with NSCLCs, between 2020-2022 were evaluated retrospectively. Treatment responses were evaluated and prognostic factors were investigated. Twenty-eight patients (70%) were men and twelve (30%) were women. Twenty-five (62.5%) patients had comorbidities. All of patients complated their treatments. Objective response rate was 72.5%. Respectively, 72.5% of patients had partial response, 27.5% of patients had stabile disease. 92.5% of patients had a reduction in primary tumor, 42.5% had lymph nodes and 75% had a reduction in stage. Seven (17.5%) patients developed Covid-2019. Passing a Covid-2019 was decreased survival (p=0.012). In conclusion; High response rates have been obtained with CRT treatment applied to NSCLC patients during the Covid-19 pandemic period. Covid-19 infection significantly reduces survival in NSCLC patients receiving CRT.

show abstract

Section: Resultsmentioning

confidence: 98%

Effect of Covid-19 pandemic on patients undergoing definitive chemoradiotherapy

Karaman¹,

Ulaş²

2022

CMJ

View full text Add to dashboard Cite

show abstract

“…This is possible thanks to the increasingly precise diagnosis of the cancer stage and precise qualification for radical treatment. Moreover, radiotherapy is becoming more technologically advanced and more effective [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy

Zaborowska-Szmit

Olszyna-Serementa

Kowalski

et al. 2021

Cancers

View full text Add to dashboard Cite

Concurrent chemoradiotherapy is recommended for locally advanced and unresectable non-small-cell lung cancer (NSCLC), but radiotherapy alone may be used in patients that are ineligible for combined-modality therapy due to poor performance status or comorbidities, which may concern elderly patients in particular. The best candidates for sequential chemoradiotherapy remain undefined. The purpose of the study was to determine the importance of a patients’ age during qualification for sequential chemoradiotherapy. The study enrolled 196 patients. Older patients (age > 65years) more often had above the median Charlson Comorbidity Index CCI > 4 (p < 0.01) and Simplified Charlson Comorbidity Index SCCI > 8 (p = 0.03), and less frequently the optimal Karnofsky Performance Score KPS = 100 (p < 0.01). There were no significant differences in histological diagnoses, frequency of stage IIIA/IIIB, weight loss, or severity of smoking between older and younger patients. Older patients experienced complete response more often (p = 0.01) and distant metastases less frequently (p = 0.03). Univariable analysis revealed as significant for overall survival: age > 65years (HR = 0.66; p = 0.02), stage IIIA (HR = 0.68; p = 0.01), weight loss > 10% (HR = 1.61; p = 0.04). Multivariable analysis confirmed age > 65years as a uniquely favorable prognostic factor (HR = 0.54; p < 0.01) independent of lung cancer disease characteristics, KPS = 100, CCI > 4, SCCI > 8. Sequential chemoradiotherapy may be considered as favorable in elderly populations.

show abstract

“…Typically, chemotherapy is pretty much better for lung cancer patients. However, still, there is an insight thought about using the standard traditional therapeutic agents [29]. All these years, there has been an increase in cancer biology studies.…”

Section: Chemotherapymentioning

confidence: 99%

Non-Small Cell Lung Cancer: Treatment, Diagnosis, and Life after Treatment

Reethi¹,

Valmiki²,

Terry³

2022

JCT

View full text Add to dashboard Cite

Lung cancer is becoming the most common cancer globally. In China, Lung cancer has become prevalent among preceding compared to present smokers. There are many treatments for lung cancer globally like Chemotherapy, Radiotherapy, Surgery, and Targeted therapy [1] [2]. Generally, lung cancer starts in the lungs. The spongy lungs in the chest inhale oxygen and exhale carbon dioxide. Those who smoke regularly have the highest risk of lung cancer than nonsmokers. This risk increases with an increase in length, time, and the number of cigarettes smoked. Immediate treatment will help in reducing the severity of cancer. The complications of lung cancer include shortness of breath, coughing up blood, pain, and fluid in the chest. Therefore, the primary step in preventing lung cancer is quitting smoking [3].

show abstract

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Abstract: Concurrent chemoradiotherapy (CHRT) remains the therapeutic standard for locally advanced inoperable non-small-cell lung cancer (NSCLC). The median overall survival (OS) with this approach is in

Cited by 9 publications

References 72 publications

Effect of Covid-19 pandemic on patients undergoing definitive chemoradiotherapy

Effect of Covid-19 pandemic on patients undergoing definitive chemoradiotherapy

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy

Non-Small Cell Lung Cancer: Treatment, Diagnosis, and Life after Treatment

Contact Info

Product

Resources

About